Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.41 |
| ▸ | AURKA | O14965 | 12/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13587823 | 0.82 | AURKA (0.37) | AURKAKDM4EGAAAURKBSYK | |
| SCHEMBL30822708 | 0.80 | AURKA (0.41) | AURKAKDM4ENPC1GAAAURKB | |
| SCHEMBL4382672 | 0.77 | PARP1 (0.41) | PARP1KDM4EGAAHSD17B10RECQL | |
| SCHEMBL30822710 | 0.72 | CYP1A2 (0.40) | PARP1AURKAKDM4ENPC1GAA | |
| SCHEMBL30822720 | 0.71 | ALK (0.49) | AURKAAURKBSYK | |
| SCHEMBL30822718 | 0.71 | TYMS (0.39) | AURKAKDM4ENPC1GAACTDSP1 | |
| SCHEMBL4383803 | 0.70 | PARP1 (0.40) | PARP1GAAHSD17B10CTDSP1RECQL | |
| SCHEMBL30822667 | 0.70 | JAK2 (0.39) | PARP1AURKAKDM4ENPC1GAA | |
| SCHEMBL30822741 | 0.70 | ALK (0.41) | PARP1AURKAKDM4EGAAAURKB | |
| SCHEMBL4383990 | 0.68 | CYP1A2 (0.39) | PARP1KDM4EHSD17B10CTDSP1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2009-12-03 | — | — | US | disclosed |
| EP-1996585-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109154-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109154-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | PARP1 1868/4885AURKA 4078/4885KDM4E 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.